Malaria Vaccine Implementation Significantly Reduces Child Mortality in Africa

A rigorous evaluation of the RTS,S malaria vaccine has confirmed a significant reduction in child deaths across the first African countries to implement the immunization program. The findings, published in the medical journal The Lancet, provide critical evidence that the vaccine is saving lives in real-world conditions and offers a viable path toward changing the trajectory of child mortality on the continent.

Real-World Impact: The MVIP Evaluation

Between 2019 and 2023, Ghana, Kenya, and Malawi served as the initial sites for the Malaria Vaccine Implementation Programme (MVIP). This large-scale evaluation assessed how the RTS,S vaccine performed outside of controlled clinical trials. The results were definitive: the vaccine is saving lives.

According to the study, approximately one in eight deaths among eligible young children were prevented in areas where the inoculations were administered. Experts anticipate that this positive impact will be matched or even exceeded in other African countries currently introducing malaria vaccines in high-burden areas.

“This is very solid evidence of the potential for malaria vaccines to change the trajectory of child mortality in Africa, and why it is urgent to overcome funding challenges to accelerate rollout,” stated Dr. Kate O’Brien, WHO Director of the Department of Immunization, Vaccines and Biologicals.

The Urgent Need for Scaled Deployment

Despite the success of the initial rollout, malaria remains a devastating threat to children under five in Africa. In 2024 alone, an estimated 438,000 African children died from the disease. The gap between the available supply and the actual delivery of the vaccine is primarily a matter of financing.

While the supply of vaccines is currently sufficient and demand remains high, more funding is required to ensure countries can purchase enough doses to reach the children most at risk of serious disease or death. The World Health Organization (WHO) emphasizes that the wide implementation of recommended vaccines—both RTS,S and the newer R21—could save tens of thousands of young lives every year if deployed at scale.

An Integrated Approach to Prevention

Health experts stress that a vaccine is not a standalone cure. To achieve the highest impact, vaccination must be part of a comprehensive, integrated strategy. The most effective results occur when countries combine the vaccine with other diagnostic and preventive measures.

Essential Malaria Control Tools

• Insecticide-treated bed nets: Providing a physical and chemical barrier against mosquitoes.
• Rapid Testing: Ensuring early and accurate diagnosis of infections.
• Timely Treatment: Administering effective medication quickly to prevent severe complications.
• Routine Immunization: Leveraging vaccine rollouts to strengthen overall childhood immunization systems.

Dr. Daniel Ngamije Madandi, Director of WHO’s malaria and neglected tropical diseases department, noted that malaria vaccination strengthens the overall response and increases access to essential prevention.

Frequently Asked Questions

Which vaccines are currently recommended for malaria?

The WHO recommends the use of the RTS,S and the newer R21 malaria vaccines.

Where was the RTS,S vaccine first evaluated in a public health setting?

The initial evaluation took place in Ghana, Kenya, and Malawi between 2019 and 2023.

Can the vaccine completely replace bed nets?

No. Vaccination works best when combined with other control measures, such as insecticide-treated bed nets and prompt medical treatment.

Looking Forward

The evidence from the MVIP evaluation marks a turning point in the fight against malaria. By proving that the RTS,S vaccine reduces childhood mortality in moderate-to-high transmission settings, the path is clear for wider adoption. The focus must now shift toward securing the necessary financing to ensure that no child in a high-burden area is left unprotected.